Floatz logo

Irinotecan

Head and Neck Neoplasms

AstraZenecaSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Head and Neck Neoplasms cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BB
Pembrolizumab
Mayo Clinic
Phase 3BB
Epirubicin
Mayo Clinic
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4B

View all 43 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →